Clearside Biomedical - CLSD Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLSD shares.
View CLSD analyst ratings or view top-rated stocks.

5 analysts have issued 12 month target prices for Clearside Biomedical's shares. Their CLSD share price forecasts range from $5.00 to $10.00. On average, they predict the company's stock price to reach $7.60 in the next twelve months. This suggests a possible upside of 544.1% from the stock's current price.
View analysts price targets for CLSD or view top-rated stocks among Wall Street analysts.

Clearside Biomedical's stock was trading at $2.75 at the start of the year. Since then, CLSD stock has decreased by 57.1% and is now trading at $1.18.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our CLSD earnings forecast.

Clearside Biomedical, Inc. (NASDAQ:CLSD) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.01. The firm had revenue of $3.07 million for the quarter, compared to analysts' expectations of $3.32 million. Clearside Biomedical had a negative net margin of 17.15% and a negative trailing twelve-month return on equity of 16.13%. During the same quarter last year, the firm earned ($0.05) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO), Ocular Therapeutix (OCUL), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Melinta Therapeutics (MLNT), OrganiGram (OGI), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Miragen Therapeutics (MGEN) and Gran Tierra Energy (GTE).

(CLSD) raised $50 million in an initial public offering (IPO) on Thursday, June 2nd 2016. The company issued 7,200,000 shares at a price of $7.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."

Clearside Biomedical's stock is owned by a variety of retail and institutional investors. Top institutional investors include ACT Capital Management LLC (3.65%), BlackRock Inc. (1.98%), Renaissance Technologies LLC (1.09%), Assenagon Asset Management S.A. (0.68%), Two Sigma Advisers LP (0.37%) and Two Sigma Investments LP (0.28%). Insiders that own company stock include Bradford T Whitmore, Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, George M Lasezkay, Nancy J Hutson, Richard T Burke, Thomas Ciulla and William D Humphries.
View institutional ownership trends.

Shares of CLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CLSD stock can currently be purchased for approximately $1.18.

Clearside Biomedical (NASDAQ:CLSD) has a market capitalization of $71.03 million and generates $29.58 million in revenue each year. The company earns $380,000.00 in net income (profit) each year or ($0.08) on an earnings per share basis.

Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The official website for the company is www.clearsidebio.com. The company can be reached via phone at (678) 270-3631, via email at charlie.deignan@clearsidebio.com, or via fax at 678-270-4033.